After UCB tried once again to block generic competition to its Parkinson’s disease patch Neupro, an appeals court has handed a win to its generic rivals.
Letters and drug alerts sent to healthcare professionals in July 2019
Moving the FDA's gears can be a lengthy process, particularly when it comes to citizen petitions. But after waiting two and a half years for regulators to stiffen impulse-control warnings on dopamine-driving Parkinson's drugs, one watchdog group ran out of patience.
China FDA ahead for UCB`s Neupro after PhIII Parkinson`s results